Devin James Emery
Insider
First SEC filing: April 29, 2021 · Latest: April 29, 2021
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 9, 2022 | CURI | F | 357 | $1.22 | $436 | 39,241 Direct | -0.90% | Disposed | 138.5% (price as of 2026-10-02) |
| Nov. 9, 2022 | CURI | F | 2,134 | $1.22 | $2,603 | 39,598 Direct | -5.11% | Disposed | 138.5% (price as of 2026-10-02) |
| Nov. 9, 2022 | CURI | F | 20 | $1.21 | $24 | 41,732 Direct | -0.05% | Disposed | 140.5% (price as of 2026-10-02) |
| Aug. 19, 2022 | CURI | F | 23 | $1.80 | $41 | 41,752 Direct | -0.06% | Disposed | 61.7% (price as of 2026-10-02) |
| July 20, 2022 | CURI | F | 20 | $2.04 | $41 | 41,775 Direct | -0.05% | Disposed | 42.6% (price as of 2026-10-02) |
| June 24, 2022 | CURI | F | 42 | $2.05 | $86 | 41,795 Direct | -0.10% | Disposed | 42.0% (price as of 2026-10-02) |
| May 20, 2022 | CURI | F | 18 | $1.62 | $29 | 41,837 Direct | -0.04% | Disposed | 79.6% (price as of 2026-10-02) |
| April 20, 2022 | CURI | F | 18 | $2.53 | $46 | 44,173 Direct | -0.04% | Disposed | 15.0% (price as of 2026-10-02) |
| March 30, 2022 | CURI | A | 384,615 | · | · | 384,615 Direct | · | Acquired | (price as of 2026-10-02) |
| March 30, 2022 | CURI | A | 99,666 | · | · | 99,666 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 18, 2022 | CURI | F | 21 | $3.51 | $74 | 48,949 Direct | -0.04% | Disposed | -17.1% (price as of 2026-10-02) |
| Jan. 20, 2022 | CURI | F | 21 | $4.55 | $96 | 48,970 Direct | -0.04% | Disposed | -36.0% (price as of 2026-10-02) |
| Dec. 23, 2021 | CURI | F | 43 | $6.44 | $277 | 48,991 Direct | -0.09% | Disposed | -54.8% (price as of 2026-10-02) |
| Dec. 20, 2021 | CURI | F | 18 | $5.70 | $103 | 49,034 Direct | -0.04% | Disposed | -48.9% (price as of 2026-10-02) |
| Nov. 19, 2021 | CURI | F | 18 | $8.03 | $145 | 41,855 Direct | -0.04% | Disposed | -63.8% (price as of 2026-10-02) |
| Nov. 5, 2021 | CURI | F | 2,240 | $9.40 | $21,056 | 41,873 Direct | -5.08% | Disposed | -69.0% (price as of 2026-10-02) |
| Oct. 20, 2021 | CURI | F | 18 | $10.57 | $190 | 44,113 Direct | -0.04% | Disposed | -72.5% (price as of 2026-10-02) |
| Sept. 24, 2021 | CURI | F | 42 | $11.09 | $466 | 44,131 Direct | -0.10% | Disposed | -73.8% (price as of 2026-10-02) |
| Sept. 20, 2021 | CURI | A | 13,824 | · | · | 13,824 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 20, 2021 | CURI | A | 2,576 | · | · | 49,052 Direct | +5.54% | Acquired | (price as of 2026-10-02) |
| July 1, 2021 | CURI | F | 42 | $14.44 | $606 | 49,052 Direct | -0.09% | Disposed | -79.8% (price as of 2026-10-02) |
| April 27, 2021 | CURI | A | 4,758 | · | · | 4,758 Direct | · | Acquired | (price as of 2026-10-02) |
| March 25, 2021 | CURI | A | 6,122 | · | · | 6,122 Direct | · | Acquired | (price as of 2026-10-02) |
| March 25, 2021 | CURI | A | 2,032 | · | · | 41,760 Direct | +5.11% | Acquired | (price as of 2026-10-02) |
| Jan. 4, 2021 | CURI | A | 12,180 | · | · | 39,728 Direct | +44.21% | Acquired | (price as of 2026-10-02) |
| Nov. 5, 2020 | CURI | A | 27,548 | · | · | 27,548 Direct | · | Acquired | (price as of 2026-10-02) |
| Nov. 2, 2020 | CURI | A | 101,571 | · | · | 101,571 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 14, 2020 | CURI | A | 47,339 | · | · | 47,339 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 30, 2022 | CURI | Stock Options (right to buy) | Common Stock | $3.01 | March 30, 2032 | 384,615 | Acquired |
| March 30, 2022 | CURI | Restricted Stock Units | Common Stock | · | · | 99,666 | Acquired |
| Sept. 20, 2021 | CURI | Stock Option (right to buy) | Common Stock | $11.60 | · | 13,824 | Acquired |
| April 27, 2021 | CURI | Stock Option (right to buy) | Common Stock | $15.00 | April 27, 2031 | 4,758 | Acquired |
| March 25, 2021 | CURI | Stock Option (right to buy) | Common Stock | $14.70 | March 24, 2031 | 6,122 | Acquired |
| Nov. 2, 2020 | CURI | Stock Option (right to buy) | Common Stock | $11.50 | Nov. 2, 2025 | 101,571 | Acquired |
| Oct. 14, 2020 | CURI | Stock Option (right to buy) | Common Stock | $4.20 | Nov. 10, 2029 | 47,339 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $314,962 | · | $299,995 | $699,999 | · | · | $26,867 | $1,341,823 |
| 2021 | $250,000 | · | $259,748 | $179,944 | $90,000 | · | $57,082 | $836,774 |
| 2020 | $250,000 | · | $273,315 | $386,986 | $62,500 | · | $54,569 | $1,027,370 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.